Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT04173494
Registration number
NCT04173494
Ethics application status
Date submitted
20/11/2019
Date registered
22/11/2019
Date last updated
1/11/2023
Titles & IDs
Public title
A Study of Momelotinib Versus Danazol in Symptomatic and Anemic Myelofibrosis Participants (MOMENTUM)
Query!
Scientific title
A Randomized, Double-blind, Phase 3 Study to Evaluate the Activity of Momelotinib (MMB) Versus Danazol (DAN) in Symptomatic, Anemic Subjects With Primary Myelofibrosis (PMF), Post-polycythemia Vera (PV) Myelofibrosis, or Post-essential Thrombocythemia (ET) Myelofibrosis Who Were Previously Treated With JAK Inhibitor Therapy
Query!
Secondary ID [1]
0
0
SRA-MMB-301
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Primary Myelofibrosis
0
0
Query!
Post-polycythemia Vera Myelofibrosis
0
0
Query!
Post-essential Thrombocythemia Myelofibrosis
0
0
Query!
Condition category
Condition code
Blood
0
0
0
0
Query!
Haematological diseases
Query!
Blood
0
0
0
0
Query!
Other blood disorders
Query!
Musculoskeletal
0
0
0
0
Query!
Other muscular and skeletal disorders
Query!
Human Genetics and Inherited Disorders
0
0
0
0
Query!
Other human genetics and inherited disorders
Query!
Cancer
0
0
0
0
Query!
Leukaemia - Chronic leukaemia
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - Momelotinib
Treatment: Drugs - Placebo to match danazol
Treatment: Drugs - Danazol
Treatment: Drugs - Placebo to match momelotinib
Experimental: Momelotinib - Participants will receive momelotinib plus placebo to match danazol
Active Comparator: Danazol - Participants will receive danazol plus placebo to match momelotinib
Treatment: Drugs: Momelotinib
Momelotinib tablets will be self-administered orally once daily
Treatment: Drugs: Placebo to match danazol
Danazol placebo capsules will be self-administered orally twice daily
Treatment: Drugs: Danazol
Danazol capsules will be self-administered orally twice daily
Treatment: Drugs: Placebo to match momelotinib
Momelotinib placebo tablets will be self-administered orally once daily
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Total Symptom Score (TSS) Response Rate at Week 24
Query!
Assessment method [1]
0
0
Myelofibrosis Symptom Assessment Form (MFSAF) TSS version (v) 4.0 response rate was defined as percentage of participants with a >= 50 percent (%) reduction from Baseline in mean MFSAF TSS over consecutive 28-day period immediately before end of Week 24. TSS response rate was measured using MFSAF v4.0. MFSAF v4.0 comprises 7 domains representing 7 most relevant symptoms of myelofibrosis (MF) identified through existing participant and clinician-based evidence: fatigue,night sweats,pruritus,abdominal discomfort,pain under left ribs,early satietyand bone pain. Participants scored each symptom domain using an 11-point numeric rating scale ranging from 0(absent) to 10(worst imaginable). The MFSAF TSS was calculated as sum of scores of 7 domains for a possible range of scores of 0 to 70, with a higher TSS corresponding to more severe symptoms. A reduction from Baseline corresponded to a lessening of MF symptoms. Baseline was the last assessment done before or on the day of first dose date.
Query!
Timepoint [1]
0
0
Baseline and Week 24
Query!
Secondary outcome [1]
0
0
Percentage of Participants With Transfusion Independence (TI) at Week 24
Query!
Assessment method [1]
0
0
TI status was defined as not receiving red blood cell (RBC) or whole blood transfusion for >=12 weeks, with no hemoglobin (Hgb) level < 8 grams per deciliter (g/dL) during the same interval. Percentage of participants with TI have been presented.
Query!
Timepoint [1]
0
0
Week 24
Query!
Secondary outcome [2]
0
0
Splenic Response Rate (SRR) of >=25% at Week 24
Query!
Assessment method [2]
0
0
Splenic response rate (SRR) is defined as the percentage of participants who have reduction in spleen volume of >=25% from Baseline at the end of Week 24. Baseline was the last assessment done before or on the day of first dose date.
Query!
Timepoint [2]
0
0
Baseline and Week 24
Query!
Secondary outcome [3]
0
0
Change From Baseline in MFSAF TSS at Week 24
Query!
Assessment method [3]
0
0
TSS was measured using the MFSAF v4.0. The MFSAF v4.0 comprises 7 domains representing the 7 most relevant symptoms of MF identified through existing participant and clinician-based evidence: fatigue, night sweats, pruritus, abdominal discomfort, pain under the left ribs, early satiety, and bone pain. Participants scored each symptom domain using an 11-point numeric rating scale ranging from 0 (absent) to 10 (worst imaginable). The MFSAF TSS was calculated as the sum of scores of the 7 domains for a possible range of scores of 0 to 70, with a higher TSS corresponding to more severe symptoms. A reduction from Baseline corresponded to a lessening of MF symptoms. Baseline was the last assessment done before or on the day of first dose date. Change from Baseline was defined as the post-Baseline value minus Baseline value.
Query!
Timepoint [3]
0
0
Baseline and Week 24
Query!
Secondary outcome [4]
0
0
Splenic Response Rate (SRR) of >= 35% at Week 24
Query!
Assessment method [4]
0
0
Splenic response rate (SRR) is defined as the percentage of participants who have reduction in spleen volume of >=35 % from Baseline at the end of Week 24. Baseline was the last assessment done before or on the day of first dose date.
Query!
Timepoint [4]
0
0
Baseline and Week 24
Query!
Secondary outcome [5]
0
0
Percentage of Participants With Zero RBC Units Transfused Over 24-Weeks
Query!
Assessment method [5]
0
0
Percentage of participants with zero RBC units transfused over 24-weeks were reported.
Query!
Timepoint [5]
0
0
Up to 24 weeks
Query!
Secondary outcome [6]
0
0
Percentage of Participants With <=4 RBC Units Transfused Over 24-weeks
Query!
Assessment method [6]
0
0
Percentage of participants with <=4 RBC units transfused over 24-weeks were reported.
Query!
Timepoint [6]
0
0
Up to 24 weeks
Query!
Secondary outcome [7]
0
0
Duration of MFSAF TSS Response
Query!
Assessment method [7]
0
0
Duration of MFSAF TSS response is defined as the number of days from the start of the initial 28-day period in which a participant had a >= 50% reduction from Baseline TSS to the first day of the 7-day assessment that determines the mean TSS for the 28-day period during which the participants TSS equals or exceeds their Baseline value.
Query!
Timepoint [7]
0
0
Up to a maximum of 151 weeks
Query!
Secondary outcome [8]
0
0
Duration of TI Response
Query!
Assessment method [8]
0
0
Duration of TI is defined as the number of days from (a) the first day of a 12-week period that satisfies the 12-week TI status definition, to (b) the first RBC transfusion or Hgb level < 8 g/dL (except in the case of clinically overt bleeding).
Query!
Timepoint [8]
0
0
Up to a maximum of 151 weeks
Query!
Secondary outcome [9]
0
0
Mean Cumulative Number of Whole Blood Units Transfused Over 24 Weeks
Query!
Assessment method [9]
0
0
Cumulative transfusion risk was calculated as the estimated mean cumulative number of whole blood units transfused during the study.
Query!
Timepoint [9]
0
0
Up to Week 24
Query!
Secondary outcome [10]
0
0
Percentage of Participants With Transfusion Dependence (TD) Status at Week 24
Query!
Assessment method [10]
0
0
TD status at Week 24 is defined as requirement of >=4 RBC units in an 8-week period immediately prior to the end of Week 24.
Query!
Timepoint [10]
0
0
Week 24
Query!
Secondary outcome [11]
0
0
Percentage of Participants With a Hemoglobin Response
Query!
Assessment method [11]
0
0
Hemoglobin responses are defined as increases of >= 1, >= 1.5, or >= 2 g/dL from Baseline in Hgb, as measured over a (rolling) period of at least 12 consecutive weeks falling entirely before the end of Week 24. Baseline was the last assessment done before or on the day of first dose date. Data has been reported for percentage of participants who had >= 1, >= 1.5, or >= 2 g/dL increase from Baseline in hemoglobin.
Query!
Timepoint [11]
0
0
Baseline and Week 24
Query!
Secondary outcome [12]
0
0
Number of Baseline TD Participants With TI Status at Week 24
Query!
Assessment method [12]
0
0
Participants were defined as having TD if they met both of the following requirements in the 8 weeks immediately before the end of Week 24: >= 4 red blood cell or whole blood units were transfused (except in the case of clinically overt bleeding), each in response to a hemoglobin assessment of <= 9.5 g/dL; and there were >= 2 hemoglobin assessments with >= 28 days between the earliest and latest hemoglobin assessments. TI status was defined as not requiring red blood cell transfusion (except in the case of clinically overt bleeding) for >= 12 weeks immediately prior to the end of Week 24, with hemoglobin levels >= 8 g/dL.
Query!
Timepoint [12]
0
0
Week 24
Query!
Secondary outcome [13]
0
0
Duration of TI in Baseline TD Participants
Query!
Assessment method [13]
0
0
Duration of TI is defined as the number of days from (a) the first day of a 12-week period that satisfies the 12-week TI status definition, to (b) the first RBC transfusion or Hgb level < 8 g/dL (except in the case of clinically overt bleeding).
Query!
Timepoint [13]
0
0
Up to a maximum of 151 weeks
Query!
Secondary outcome [14]
0
0
Number of Participants With Serious Adverse Events (SAEs) and Non-serious Adverse Events (Non-SAEs)- up to Week 24
Query!
Assessment method [14]
0
0
An adverse event (AE) is any untoward medical occurrence in a trial participant administered an investigational product(s), a comparator product, or an approved drug regardless of the causal relationship with treatment. An SAE is an AE that Results in death, life threatening, requires inpatient hospitalization or prolongation of an existing hospitalization, results in persistent or significant disability or incapacity, results in a congenital anomaly/birth defect or any important medical events as per medical or scientific judgment. Adverse events which were not Serious were considered as Non-Serious adverse events.
Query!
Timepoint [14]
0
0
Up to Week 24
Query!
Secondary outcome [15]
0
0
Number of Participants With Serious Adverse Events (SAEs) and Non-serious Adverse Events (Non-SAEs)- From Week 24 to a Maximum of 151 Weeks
Query!
Assessment method [15]
0
0
An AE is any untoward medical occurrence in a trial participant administered an investigational product(s), a comparator product, or an approved drug regardless of the causal relationship with treatment. An SAE is an AE that Results in death, life threatening, requires inpatient hospitalization or prolongation of an existing hospitalization, results in persistent or significant disability or incapacity, results in a congenital anomaly/birth defect or any important medical events as per medical or scientific judgment. Adverse events which were not Serious were considered as Non-Serious adverse events.
Query!
Timepoint [15]
0
0
From Week 24 to a maximum of 151 weeks
Query!
Secondary outcome [16]
0
0
Overall Survival (OS)
Query!
Assessment method [16]
0
0
Overall survival is defined as the interval from the first study drug dosing date (or randomization date for participants who did not receive treatment) to death from any cause.
Query!
Timepoint [16]
0
0
Up to a maximum of 151 weeks
Query!
Secondary outcome [17]
0
0
Leukemia-free Survival (LFS)
Query!
Assessment method [17]
0
0
LFS is defined as the interval from first study drug dosing date (or randomization date for participants who did not receive treatment) to any evidence of leukemic transformation and/or death (from any cause).
Query!
Timepoint [17]
0
0
Up to a maximum of 151 weeks
Query!
Secondary outcome [18]
0
0
Change From Baseline in Disease-related Fatigue as Assessed by MFSAF TSS v4.0 at Week 24
Query!
Assessment method [18]
0
0
The MFSAF v4.0 comprises 7 domains representing the 7 most relevant symptoms of MF identified through existing participant- and clinician-based evidence: fatigue, night sweats, pruritus, abdominal discomfort, pain under the left ribs, early satiety, and bone pain. Participants scored each symptom domain using an 11-point numeric rating scale ranging from 0 (absent) to 10 (worst imaginable). Data has been reported for Disease-related Fatigue domain measured using an 11-point numeric rating scale ranging from 0 (absent) to 10 (worst imaginable), higher score indicates worst outcome. An increase in score from Baseline indicated a worsening of fatigue and a decrease in score from Baseline indicated an improvement in fatigue. Baseline was the last assessment done before or on the day of first dose date. Change from Baseline was defined as the post-Baseline value minus Baseline value.
Query!
Timepoint [18]
0
0
Baseline and Week 24
Query!
Secondary outcome [19]
0
0
Change From Baseline in Cancer-related Fatigue as Assessed by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) at Week 24
Query!
Assessment method [19]
0
0
The EORTC QLQ-C30 is comprised of 5 functional scales (physical, role, emotional, social, cognitive), eight single item symptom scales (fatigue, pain, nausea/vomiting, appetite loss, constipation, diarrhea, insomnia, dyspnea), as well as sub-scales assessing global health/quality of life and financial impact. Most items use a 4-point Likert scale from "not at all" to "very much" and a one-week recall period with the exception of the final two items which use a 7 point scale response from "very poor" to "excellent". Scores were averaged and transformed to a 0-100 scale, with higher scores representing better functioning/quality of life. An increase in scores from Baseline indicated an improved functioning/quality of life, and a decrease in scores from Baseline indicated a worsened functioning/quality of life. Baseline was the last assessment done before or on the day of first dose date. Change from Baseline was defined as the post-Baseline value minus Baseline value.
Query!
Timepoint [19]
0
0
Baseline and Week 24
Query!
Secondary outcome [20]
0
0
Change From Baseline in Physical Function Score as Assessed by Patient-Reported Outcomes Measurement Information System (PROMIS) Physical Function Short Form 10b at Week 24
Query!
Assessment method [20]
0
0
PROMIS Physical Function Short Form 10b consists of 14 questions; each with a 5-point response. PROMIS short form assesses self-reported capability of a participant rather than actual performance of physical activities. This includes functioning of one's upper extremities (dexterity), lower extremities (walking or mobility), and central regions (neck, back) as well as instrumental activities of daily living, such as running errands. Participants scored each response on a scale from 1 (unable to do) to 5 (without any difficulty, or not at all). Total possible range of scores was 14 to 70, with higher scores corresponding to a greater physical function ability. An increase in score from Baseline indicated an improvement in physical function ability and a decrease in score from Baseline indicated a reduction in physical function ability. Baseline was last assessment done before or on the day of first dose date. Change from Baseline was defined as post-Baseline value minus Baseline value.
Query!
Timepoint [20]
0
0
Baseline and Week 24
Query!
Eligibility
Key inclusion criteria
- Age >= 18 years.
- Confirmed diagnosis of PMF in accordance with the World Health Organization (WHO) 2016
criteria, or Post- polycythemia vera/essential thrombocythemia (PV/ET) MF in
accordance with the International Working Group-Myeloproliferative Neoplasms Research
and Treatment (IWG-MRT criteria).
- Symptomatic, defined as a TSS of >= 10 units assessed by a single MFSAF v4.0
assessment during Screening prior to Baseline period (Day BL1).
- Anemic, defined as a Hgb < 10 g/dL in Screening/Baseline period.
- Previously treated with an approved JAK inhibitor for PMF or Post-PV/ET MF for >= 90
days, or >= 28 days if JAK inhibitor therapy is complicated by RBC transfusion
requirement of >= 4 units in 8 weeks, or Grade 3/4 AEs of thrombocytopenia, anemia, or
hematoma.
- Baseline splenomegaly, defined as having a palpable spleen at >= 5 centimeter (cm),
below the left costal margin, or with volume >= 450 cubic centimeter (cm^3) on imaging
(ultrasound, magnetic resonance imaging [MRI] or computed tomography [CT] are
acceptable), assessed during Screening at any point prior to Randomization.
- High risk, intermediate-2, or intermediate-1 risk MF as defined by Dynamic
International Prognostic Scoring System (DIPSS), or DIPSS-plus.
- No allogeneic stem cell transplant planned.
- Acceptable laboratory assessments:
1. Absolute neutrophil count (ANC) >= 0.75 × 10^9/Liter (L).
2. Platelet count (PLT) >= 25 × 10^9/L (without requirement for platelet
transfusion).
3. Peripheral blast count < 10%.
4. Alanine aminotransferase/ glutamic-oxaloacetic transaminase (AST/SGOT) and
alanine aminotransferase/ serum glutamic-pyruvic transaminase (ALT/SGPT) <= 3 ×
Upper Limit Normal (ULN) (<= 5 × ULN if liver is involved by extramedullary
hematopoiesis as judged by the investigator or if related to iron chelator
therapy that was started within the prior 60 days).
5. Calculated creatinine clearance (CCr) >= 30 milliliter per minute (mL/min)
according to Cockcroft-Gault.
6. Direct bilirubin <= 2.0 × ULN.
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
- Use of the following treatments within the time periods noted:
1. Prior momelotinib treatment at any time.
2. Approved JAK inhibitor therapy (eg, fedratinib or ruxolitinib) within 1 week
prior to the first day of Baseline.
3. Active anti-MF therapy within 1 week prior to the first day of Baseline.
4. Potent Cytochrome P450 3A4 (CYP3A4) inducers within 1 week prior to
Randomization.
5. Investigational agent (including investigational JAK inhibitors) within 4 weeks
prior to Randomization.
6. Erythropoiesis stimulating agent (ESA) within 4 weeks prior to Randomization.
7. Danazol within 3 months prior to Randomization.
8. Splenic irradiation within 3 months prior to Randomization.
9. Current treatment with simvastatin, atorvastatin, lovastatin or rosuvastatin.
- History of prostate cancer, with the exception of localized prostate cancer that has
been treated surgically or by radiotherapy with curative intent and presumed cured.
- Prostate specific antigen (PSA) > 4 nanograms per milliliter (ng/mL).
- Unsuitable for spleen volume measurements due to prior splenectomy or unwilling or
unable to undergo an MRI scan or CT scan for spleen volume measurement per protocol
requirements.
- Any of the following (criteria a - k):
1. Uncontrolled intercurrent illness including, but not limited to: active
uncontrolled infection (participants receiving outpatient antibacterial and/or
antiviral treatments for infection that is under control or as infection
prophylaxis may be included in the trial).
2. Significant active or chronic bleeding event >= Grade 2 per Common Terminology
Criteria for Adverse Events (CTCAE) v5.0, within 4 weeks prior to Randomization.
3. Unstable angina pectoris within 6 months prior to Randomization.
4. Symptomatic congestive heart failure within 6 months prior to Randomization.
5. Uncontrolled cardiac arrhythmia within 6 months prior to Randomization.
6. QT Interval Corrected Using Fridericia's Formula (QTcF) interval > 500
millisecond (msec), unless attributed to bundle branch block.
7. Current progressive thrombosis despite treatment.
8. History of porphyria.
9. Child-Pugh score >= 10.
10. Psychiatric illness, social situation, or any other condition that would limit
compliance with trial requirements or may interfere with the interpretation of
study results, as judged by investigator or sponsor.
11. Inability or unwillingness to comply with the protocol restrictions on MF therapy
and other medications prior to and during study treatment.
- Participants with a prior or concurrent malignancy, whose natural history or treatment
has a significant potential to interfere with the safety or efficacy assessment of the
investigational regimen.
- Known clinically significant anemia due to iron, vitamin B12, or folate deficiencies,
or autoimmune or hereditary hemolytic anemia, or gastrointestinal bleeding or
thalassemia.
- Known positive status for human immunodeficiency viruses (HIV).
- Chronic active or acute viral hepatitis A, B, or C infection, or hepatitis B or C
carrier (testing required for hepatitis B and C).
- Unresolved non-hematologic toxicities from prior therapies that are > Grade 1 per
CTCAE v5.0.
- Presence of peripheral neuropathy >= Grade 2 per CTCAE v5.0.
- Women who are already pregnant or lactating. Additional inclusion/exclusion criteria
may apply.
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
7/02/2020
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
29/12/2022
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
195
Query!
Recruitment in Australia
Recruitment state(s)
ACT,NSW,SA,VIC,WA
Query!
Recruitment hospital [1]
0
0
Canberra Region Cancer Centre - Garran
Query!
Recruitment hospital [2]
0
0
Calvary Mater Newcastle Hospital - Waratah
Query!
Recruitment hospital [3]
0
0
Flinders Medical Centre - Bedford Park
Query!
Recruitment hospital [4]
0
0
The Alfred Hospital - Melbourne
Query!
Recruitment hospital [5]
0
0
Perth Radiological Clinic - Magnetic Resonance Centre - Perth
Query!
Recruitment postcode(s) [1]
0
0
2605 - Garran
Query!
Recruitment postcode(s) [2]
0
0
2298 - Waratah
Query!
Recruitment postcode(s) [3]
0
0
5042 - Bedford Park
Query!
Recruitment postcode(s) [4]
0
0
3004 - Melbourne
Query!
Recruitment postcode(s) [5]
0
0
6000 - Perth
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Arizona
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
California
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Colorado
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
District of Columbia
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Florida
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Illinois
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Missouri
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
New Jersey
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
New York
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
Ohio
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
Pennsylvania
Query!
Country [12]
0
0
United States of America
Query!
State/province [12]
0
0
Texas
Query!
Country [13]
0
0
Austria
Query!
State/province [13]
0
0
Tyrol
Query!
Country [14]
0
0
Austria
Query!
State/province [14]
0
0
Upper Austria
Query!
Country [15]
0
0
Austria
Query!
State/province [15]
0
0
Vienna
Query!
Country [16]
0
0
Austria
Query!
State/province [16]
0
0
Steyr
Query!
Country [17]
0
0
Belgium
Query!
State/province [17]
0
0
Brussels
Query!
Country [18]
0
0
Belgium
Query!
State/province [18]
0
0
Hainaut
Query!
Country [19]
0
0
Belgium
Query!
State/province [19]
0
0
West-Vlaanderen
Query!
Country [20]
0
0
Belgium
Query!
State/province [20]
0
0
Antwerpen
Query!
Country [21]
0
0
Belgium
Query!
State/province [21]
0
0
Liège
Query!
Country [22]
0
0
Bulgaria
Query!
State/province [22]
0
0
Pleven
Query!
Country [23]
0
0
Bulgaria
Query!
State/province [23]
0
0
Sofia
Query!
Country [24]
0
0
Canada
Query!
State/province [24]
0
0
British Columbia
Query!
Country [25]
0
0
Canada
Query!
State/province [25]
0
0
Nova Scotia
Query!
Country [26]
0
0
Canada
Query!
State/province [26]
0
0
Ontario
Query!
Country [27]
0
0
Canada
Query!
State/province [27]
0
0
Quebec
Query!
Country [28]
0
0
Canada
Query!
State/province [28]
0
0
Québec
Query!
Country [29]
0
0
Czechia
Query!
State/province [29]
0
0
Jihormoravsky Kraj
Query!
Country [30]
0
0
Denmark
Query!
State/province [30]
0
0
Hovedstaden
Query!
Country [31]
0
0
Denmark
Query!
State/province [31]
0
0
Nordjylland
Query!
Country [32]
0
0
Denmark
Query!
State/province [32]
0
0
Sjælland
Query!
Country [33]
0
0
Denmark
Query!
State/province [33]
0
0
Syddanmark
Query!
Country [34]
0
0
France
Query!
State/province [34]
0
0
Aquitaine
Query!
Country [35]
0
0
France
Query!
State/province [35]
0
0
Basse-Normandie
Query!
Country [36]
0
0
France
Query!
State/province [36]
0
0
Hauts-de-France
Query!
Country [37]
0
0
France
Query!
State/province [37]
0
0
Ile-de-France
Query!
Country [38]
0
0
France
Query!
State/province [38]
0
0
Limousin
Query!
Country [39]
0
0
France
Query!
State/province [39]
0
0
Nord Pas-Des-Calais
Query!
Country [40]
0
0
France
Query!
State/province [40]
0
0
Pays De La Loire
Query!
Country [41]
0
0
France
Query!
State/province [41]
0
0
Picardie
Query!
Country [42]
0
0
France
Query!
State/province [42]
0
0
Provence-Alpes-Côte d'Azur
Query!
Country [43]
0
0
France
Query!
State/province [43]
0
0
Rhone-Alps
Query!
Country [44]
0
0
France
Query!
State/province [44]
0
0
Angers
Query!
Country [45]
0
0
France
Query!
State/province [45]
0
0
Lille
Query!
Country [46]
0
0
France
Query!
State/province [46]
0
0
Marseille
Query!
Country [47]
0
0
France
Query!
State/province [47]
0
0
Mulhouse
Query!
Country [48]
0
0
France
Query!
State/province [48]
0
0
Nantes
Query!
Country [49]
0
0
France
Query!
State/province [49]
0
0
Poitiers
Query!
Country [50]
0
0
Germany
Query!
State/province [50]
0
0
Nordrhein-Westfalen
Query!
Country [51]
0
0
Germany
Query!
State/province [51]
0
0
Sachsen-Anhalt
Query!
Country [52]
0
0
Germany
Query!
State/province [52]
0
0
Sachsen
Query!
Country [53]
0
0
Germany
Query!
State/province [53]
0
0
Thuringen
Query!
Country [54]
0
0
Germany
Query!
State/province [54]
0
0
Köln
Query!
Country [55]
0
0
Germany
Query!
State/province [55]
0
0
Lübeck
Query!
Country [56]
0
0
Germany
Query!
State/province [56]
0
0
Mutlangen
Query!
Country [57]
0
0
Hungary
Query!
State/province [57]
0
0
Baranya
Query!
Country [58]
0
0
Hungary
Query!
State/province [58]
0
0
Hajdu-Bihar
Query!
Country [59]
0
0
Hungary
Query!
State/province [59]
0
0
Komárom-Esztergom
Query!
Country [60]
0
0
Hungary
Query!
State/province [60]
0
0
Pest
Query!
Country [61]
0
0
Hungary
Query!
State/province [61]
0
0
Somogy
Query!
Country [62]
0
0
Hungary
Query!
State/province [62]
0
0
Szabolcs-Szatmár-Bereg
Query!
Country [63]
0
0
Hungary
Query!
State/province [63]
0
0
Vas
Query!
Country [64]
0
0
Hungary
Query!
State/province [64]
0
0
Budapest
Query!
Country [65]
0
0
Hungary
Query!
State/province [65]
0
0
Gyor
Query!
Country [66]
0
0
Israel
Query!
State/province [66]
0
0
Central District
Query!
Country [67]
0
0
Israel
Query!
State/province [67]
0
0
Haifa District
Query!
Country [68]
0
0
Israel
Query!
State/province [68]
0
0
Jerusalem District
Query!
Country [69]
0
0
Israel
Query!
State/province [69]
0
0
Haifa
Query!
Country [70]
0
0
Israel
Query!
State/province [70]
0
0
Jerusalem
Query!
Country [71]
0
0
Israel
Query!
State/province [71]
0
0
Kfar Saba
Query!
Country [72]
0
0
Israel
Query!
State/province [72]
0
0
Nahariya
Query!
Country [73]
0
0
Israel
Query!
State/province [73]
0
0
Petah tikva
Query!
Country [74]
0
0
Israel
Query!
State/province [74]
0
0
Tel Aviv
Query!
Country [75]
0
0
Italy
Query!
State/province [75]
0
0
Florence
Query!
Country [76]
0
0
Italy
Query!
State/province [76]
0
0
Foggia
Query!
Country [77]
0
0
Italy
Query!
State/province [77]
0
0
Forli-Cesena
Query!
Country [78]
0
0
Italy
Query!
State/province [78]
0
0
Monza E Brianza
Query!
Country [79]
0
0
Italy
Query!
State/province [79]
0
0
Pesaro E Urbino
Query!
Country [80]
0
0
Italy
Query!
State/province [80]
0
0
Potenza
Query!
Country [81]
0
0
Italy
Query!
State/province [81]
0
0
Turin
Query!
Country [82]
0
0
Italy
Query!
State/province [82]
0
0
Alessandria
Query!
Country [83]
0
0
Italy
Query!
State/province [83]
0
0
Bologna
Query!
Country [84]
0
0
Italy
Query!
State/province [84]
0
0
Genova
Query!
Country [85]
0
0
Italy
Query!
State/province [85]
0
0
Milano
Query!
Country [86]
0
0
Italy
Query!
State/province [86]
0
0
Napoli
Query!
Country [87]
0
0
Italy
Query!
State/province [87]
0
0
Novara
Query!
Country [88]
0
0
Italy
Query!
State/province [88]
0
0
Roma
Query!
Country [89]
0
0
Italy
Query!
State/province [89]
0
0
Udine
Query!
Country [90]
0
0
Italy
Query!
State/province [90]
0
0
Varese
Query!
Country [91]
0
0
Italy
Query!
State/province [91]
0
0
Verona
Query!
Country [92]
0
0
Korea, Republic of
Query!
State/province [92]
0
0
Daegu Gwang'yeogsi
Query!
Country [93]
0
0
Korea, Republic of
Query!
State/province [93]
0
0
Busan
Query!
Country [94]
0
0
Korea, Republic of
Query!
State/province [94]
0
0
Seongnam-si
Query!
Country [95]
0
0
Korea, Republic of
Query!
State/province [95]
0
0
Seoul
Query!
Country [96]
0
0
Korea, Republic of
Query!
State/province [96]
0
0
Ulsan
Query!
Country [97]
0
0
New Zealand
Query!
State/province [97]
0
0
Auckland
Query!
Country [98]
0
0
Poland
Query!
State/province [98]
0
0
Dolnoslaskie
Query!
Country [99]
0
0
Poland
Query!
State/province [99]
0
0
Lubelskie
Query!
Country [100]
0
0
Poland
Query!
State/province [100]
0
0
Malopolskie
Query!
Country [101]
0
0
Poland
Query!
State/province [101]
0
0
Mazowieckie
Query!
Country [102]
0
0
Poland
Query!
State/province [102]
0
0
Opolskie
Query!
Country [103]
0
0
Poland
Query!
State/province [103]
0
0
Pomorskie
Query!
Country [104]
0
0
Poland
Query!
State/province [104]
0
0
Salskie
Query!
Country [105]
0
0
Poland
Query!
State/province [105]
0
0
Lódz
Query!
Country [106]
0
0
Romania
Query!
State/province [106]
0
0
Dolj
Query!
Country [107]
0
0
Romania
Query!
State/province [107]
0
0
Iasi County
Query!
Country [108]
0
0
Romania
Query!
State/province [108]
0
0
Mure?
Query!
Country [109]
0
0
Romania
Query!
State/province [109]
0
0
Brasov
Query!
Country [110]
0
0
Romania
Query!
State/province [110]
0
0
Bucharest
Query!
Country [111]
0
0
Singapore
Query!
State/province [111]
0
0
Singapore
Query!
Country [112]
0
0
Spain
Query!
State/province [112]
0
0
Asturias
Query!
Country [113]
0
0
Spain
Query!
State/province [113]
0
0
Barcelona
Query!
Country [114]
0
0
Spain
Query!
State/province [114]
0
0
Cáceres
Query!
Country [115]
0
0
Spain
Query!
State/province [115]
0
0
Girona
Query!
Country [116]
0
0
Spain
Query!
State/province [116]
0
0
Madrid
Query!
Country [117]
0
0
Spain
Query!
State/province [117]
0
0
Málaga
Query!
Country [118]
0
0
Spain
Query!
State/province [118]
0
0
Salamanca
Query!
Country [119]
0
0
Spain
Query!
State/province [119]
0
0
Sevilla
Query!
Country [120]
0
0
Spain
Query!
State/province [120]
0
0
Valencia
Query!
Country [121]
0
0
Spain
Query!
State/province [121]
0
0
Zaragoza
Query!
Country [122]
0
0
Sweden
Query!
State/province [122]
0
0
Stockholm
Query!
Country [123]
0
0
Sweden
Query!
State/province [123]
0
0
Västra Götalands Län
Query!
Country [124]
0
0
Sweden
Query!
State/province [124]
0
0
Uddevalla
Query!
Country [125]
0
0
Taiwan
Query!
State/province [125]
0
0
Chaiyi
Query!
Country [126]
0
0
Taiwan
Query!
State/province [126]
0
0
Taichung
Query!
Country [127]
0
0
Taiwan
Query!
State/province [127]
0
0
Taipei
Query!
Country [128]
0
0
Taiwan
Query!
State/province [128]
0
0
Taoyuan
Query!
Country [129]
0
0
United Kingdom
Query!
State/province [129]
0
0
England
Query!
Country [130]
0
0
United Kingdom
Query!
State/province [130]
0
0
Scotland
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
Sierra Oncology LLC - a GSK company
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
MOMENTUM is a randomized, double-blind, active control Phase 3 trial intended to confirm the
differentiated clinical benefits of the investigational drug momelotinib (MMB) versus danazol
(DAN) in symptomatic and anemic participants who have previously received an approved Janus
kinase inhibitor (JAKi) therapy for myelofibrosis (MF). The purpose of this clinical study is
to compare the effectiveness and safety of MMB to DAN in treating and reducing: 1) disease
related symptoms, 2) the need for blood transfusions and 3) splenomegaly, in adults with
primary MF, post-polycythemia vera MF or post-essential thrombocythemia MF. The study is
planned in countries including, but not limited to: Australia, Austria, Belgium, Bulgaria,
Canada, Czech Republic, Denmark, France, Germany, Hungary, Israel, Italy, New Zealand,
Poland, Romania, Singapore, South Korea, Spain, Sweden, Taiwan, United Kingdom (UK) and
United States (US).
Participants must be symptomatic with a Myelofibrosis Symptom Assessment Form (MFSAF) version
(v) 4.0 Total Symptom Score of >= 10 at screening, and be anemic with hemoglobin (Hgb) < 10
gram/deciliter (g/dL). For participants with ongoing JAKi therapy at screening, JAKi therapy
must be tapered over a period of at least 1 week, followed by a 2-week non-treatment washout
interval prior to randomization.
Participants will be randomized 2:1 to orally self-administer blinded treatment: MMB plus
placebo or DAN plus placebo. Participants randomized to receive MMB who complete the
randomized treatment period to the end of Week 24 may continue to receive MMB in the
open-label extended treatment period to the end of Week 204 (a total period of treatment of
approximately 4 years) if the participants tolerates and continues to benefit from MMB.
Participants randomized to receive DAN may cross-over to MMB open-label treatment in the
following circumstances: at the end of Week 24 if they complete the randomized treatment
period; or at the end of Week 24 if they discontinue treatment with DAN but continue study
assessments and do not receive prohibited medications including alternative active anti-MF
therapy; or at any time during the randomized treatment period if they meet the
protocol-defined criteria for radiographically confirmed symptomatic splenic progression.
Participants randomized to receive DAN who are receiving clinical benefit at the end of Week
24 may choose to continue DAN therapy up to Week 48. The comparator treatment, DAN, is an
approved medication in the US and in some other countries and is recommended by national
guidelines as a treatment for anemia in MF.
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT04173494
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Srdan Verstovsek, M.D., Ph.D.
Query!
Address
0
0
Department of Leukemia, The University of Texas MD Anderson Cancer Center
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT04173494
Download to PDF